Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001))

Ian Chau; Markus Peck-Radosavljevic; Christophe Borg; Peter Malfertheiner; Jean Francois Seitz; Joon Oh Park; Baek Yeol Ryoo; Chia Jui Yen; Masatoshi Kudo; Ronnie Poon; Davide Pastorelli; Jean Frederic Blanc; Hyun Cheol Chung; Ari D. Baron; Takuji Okusaka; L. Bowman; Zhanglin Lin Cui; Allicia C. Girvan; Paolo B. Abada; Ling Yang; Andrew X. Zhu

doi:10.1016/j.ejca.2018.06.002

Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001))

Ian Chau, Markus Peck-Radosavljevic, Christophe Borg, Peter Malfertheiner, Jean Francois Seitz, Joon Oh Park, Baek Yeol Ryoo, Chia Jui Yen, Masatoshi Kudo, Ronnie Poon, Davide Pastorelli, Jean Frederic Blanc, Hyun Cheol Chung, Ari D. Baron, Takuji Okusaka, L. Bowman, Zhanglin Lin Cui, Allicia C. Girvan, Paolo B. Abada, Ling YangAndrew X. Zhu

Department of Internal Medicine

Research output: Contribution to journal › Comment/debate › peer-review

5 Citations (Scopus)

Abstract

The authors regret that, in Fig. 4, a hazard ratio was missing for the FHSI-8 symptom item Discomfort or Pain in Stomach. Please see the corrected figure here. [Figure presented] The authors would like to apologise for any inconvenience caused.

Original language	English
Pages (from-to)	135-136
Number of pages	2
Journal	European Journal of Cancer
Volume	100
DOIs	https://doi.org/10.1016/j.ejca.2018.06.002
Publication status	Published - 2018 Sept

Bibliographical note

Publisher Copyright:
© 2018 Elsevier Ltd

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2018.06.002

Fingerprint

Dive into the research topics of 'Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001))'. Together they form a unique fingerprint.

Cite this

Chau, I., Peck-Radosavljevic, M., Borg, C., Malfertheiner, P., Seitz, J. F., Park, J. O., Ryoo, B. Y., Yen, C. J., Kudo, M., Poon, R., Pastorelli, D., Blanc, J. F., Chung, H. C., Baron, A. D., Okusaka, T., Bowman, L., Cui, Z. L., Girvan, A. C., Abada, P. B., ... Zhu, A. X. (2018). Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001)). European Journal of Cancer, 100, 135-136. https://doi.org/10.1016/j.ejca.2018.06.002

Chau, Ian ; Peck-Radosavljevic, Markus ; Borg, Christophe et al. / Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib : Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001)). In: European Journal of Cancer. 2018 ; Vol. 100. pp. 135-136.

@article{a801abeeb61a4dd4b9c5830d3cba7c14,

title = "Corrigendum to {\textquoteleft}Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study{\textquoteright} [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001))",

abstract = "The authors regret that, in Fig. 4, a hazard ratio was missing for the FHSI-8 symptom item Discomfort or Pain in Stomach. Please see the corrected figure here. [Figure presented] The authors would like to apologise for any inconvenience caused.",

author = "Ian Chau and Markus Peck-Radosavljevic and Christophe Borg and Peter Malfertheiner and Seitz, {Jean Francois} and Park, {Joon Oh} and Ryoo, {Baek Yeol} and Yen, {Chia Jui} and Masatoshi Kudo and Ronnie Poon and Davide Pastorelli and Blanc, {Jean Frederic} and Chung, {Hyun Cheol} and Baron, {Ari D.} and Takuji Okusaka and L. Bowman and Cui, {Zhanglin Lin} and Girvan, {Allicia C.} and Abada, {Paolo B.} and Ling Yang and Zhu, {Andrew X.}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Ltd",

year = "2018",

month = sep,

doi = "10.1016/j.ejca.2018.06.002",

language = "English",

volume = "100",

pages = "135--136",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

Chau, I, Peck-Radosavljevic, M, Borg, C, Malfertheiner, P, Seitz, JF, Park, JO, Ryoo, BY, Yen, CJ, Kudo, M, Poon, R, Pastorelli, D, Blanc, JF, Chung, HC, Baron, AD, Okusaka, T, Bowman, L, Cui, ZL, Girvan, AC, Abada, PB, Yang, L & Zhu, AX 2018, 'Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001))', European Journal of Cancer, vol. 100, pp. 135-136. https://doi.org/10.1016/j.ejca.2018.06.002

Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib : Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001)). / Chau, Ian; Peck-Radosavljevic, Markus; Borg, Christophe et al.

In: European Journal of Cancer, Vol. 100, 09.2018, p. 135-136.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib

T2 - Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001))

AU - Chau, Ian

AU - Peck-Radosavljevic, Markus

AU - Borg, Christophe

AU - Malfertheiner, Peter

AU - Seitz, Jean Francois

AU - Park, Joon Oh

AU - Ryoo, Baek Yeol

AU - Yen, Chia Jui

AU - Kudo, Masatoshi

AU - Poon, Ronnie

AU - Pastorelli, Davide

AU - Blanc, Jean Frederic

AU - Chung, Hyun Cheol

AU - Baron, Ari D.

AU - Okusaka, Takuji

AU - Bowman, L.

AU - Cui, Zhanglin Lin

AU - Girvan, Allicia C.

AU - Abada, Paolo B.

AU - Yang, Ling

AU - Zhu, Andrew X.

PY - 2018/9

Y1 - 2018/9

N2 - The authors regret that, in Fig. 4, a hazard ratio was missing for the FHSI-8 symptom item Discomfort or Pain in Stomach. Please see the corrected figure here. [Figure presented] The authors would like to apologise for any inconvenience caused.

AB - The authors regret that, in Fig. 4, a hazard ratio was missing for the FHSI-8 symptom item Discomfort or Pain in Stomach. Please see the corrected figure here. [Figure presented] The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85049333639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049333639&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2018.06.002

DO - 10.1016/j.ejca.2018.06.002

M3 - Comment/debate

C2 - 29970352

AN - SCOPUS:85049333639

SN - 0959-8049

VL - 100

SP - 135

EP - 136

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO et al. Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001)). European Journal of Cancer. 2018 Sept;100:135-136. doi: 10.1016/j.ejca.2018.06.002